2 terminated, 1 active not recruiting, 1 completed, 1 unknown. 5 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Terminated 2, Active not recruiting 1, Completed 1, Unknown 1 |
| Phase 2 | 3 | Terminated 2, Unknown 1 |
Follow Nerve Degeneration: new trials by email Literature Review of Nerve Degeneration trials Research Report on Nerve Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing Cognitive Decline with Metformin Metformin XR, 500-2000mg nocte - Cognitive Decline | Phase 3 | Active not recruiting | Garvan Institute of Medical Research | 242 | 2022-07-15 | 2024-10-02 |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction Dextromethorphan, Memantine, Dextromethorphan and memantine - Amphetamine Addiction, Pharmacotherapy | Phase 2 / Phase 3 | Unknown | National Cheng-Kung University Hospital | 120 | 2020-08-11 | 2020-12-29 |
| Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency Copper Histidine - Menkes Disease, Occipital Horn Syndrome | Phase 3 | Completed | Cyprium Therapeutics, Inc. | 93 | 2009-02-27 | 2020-11-19 |
| Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Lithium Carbonate, Riluzole, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Terminated | Massachusetts General Hospital | 84 | 2009-01-01 | 2011-04-19 |
Inflammation (2) · Amphetamine-Related Disorders (1) · Amyotrophic Lateral Sclerosis (1) · Cerebrovascular Disorders (1) · Cognitive Dysfunction (1) · Dementia (1) · Diabetes Mellitus (1) · Diffuse Cerebral Sclerosis of Schilder (1) · Drug Resistant Epilepsy (1) · Insulin Resistance (1) · Leigh Disease (1) · MELAS Syndrome (1) · MERRF Syndrome (1) · Menkes Kinky Hair Syndrome (1)
Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Central Nervous System Diseases (4) · Metabolic Diseases (4) · Nervous System Diseases (4) · Nutritional and Metabolic Diseases (4) · Brain Diseases (3) · Brain Diseases, Metabolic (2) · Brain Diseases, Metabolic, Inborn (2) · Cardiovascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Mental Disorders (2) · Metabolism, Inborn Errors (2) · Neurologic Manifestations (2)
Dextromethorphan (1) · Lithium Carbonate (1) · Memantine (1) · Riluzole (1) · alpha-tocotrienol quinone (1) · copper histidine (1)
Cyprium Therapeutics, Inc. (1) · Garvan Institute of Medical Research (1) · Massachusetts General Hospital (1) · National Cheng-Kung University Hospital (1) · PTC Therapeutics (1)
United States (3) · Canada (2) · Australia (1) · France (1) · Italy (1) · Japan (1) · Poland (1) · Spain (1) · Sweden (1) · Taiwan (1) · United Kingdom (1)
Jinsy Andrews, MD (1) · Lorne Zinman, MD, MSc, FRCPC (1) · Merit Cudkowicz, MD, MSc (1) · Swati Aggarwal, MD (1) · Tzu-Yun Wang (1) · Vinay Penematsa, MD (1)
U01NS049640 (1)